top of page
Akamis Bio News-Web-12.jpg

News Archives

January 5, 2023

Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics

August 11, 2022

PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer

September 15, 2021

PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T-SIGn® vector, NG-350A, to Re-Engineer Advanced Cancers

April 14, 2021

PsiOxus and bluebird bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases

April 7, 2021

PsiOxus Therapeutics updates agreement with Bristol-Myers Squibb to advance their clinical stage immuno-oncology collaboration

bottom of page